Cardiovascular disease and 1,5-anhydro-d-glucitol

  • Ikeda Nobutaka
    Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
  • Hiroi Yukio
    Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan.

抄録

<p>The serum 1,5-anhydro-d-glucitol (1,5-AG) level rapidly decreases concomitantly with urinary glucose excretion in hyperglycemia. 1,5-AG is a sensitive clinical marker of short-term glycemic control, postprandial hyperglycemia and glucose fluctuation. Increasing evidence about the relationship between cardiovascular disease (CVD) and glucose fluctuations have been published. In this review, we summarize the possibilities and limitations of 1,5-AG as a marker of CVD. Research showed that 1,5-AG level is associated with prevalence of CVD and is also a predictive value for cardiovascular (CV) events. Especially in a high risk population, the predictive value of 1,5-AG for CV events becomes more effective. Besides, 1,5-AG is an effective glycometabolic marker that complements HbA1c in terms of glucose fluctuation. Appropriate use of 1,5-AG might lead to improved prognosis for patients or decrease medical financial burden of the population through early detection of glucose disorder and quality glucose control.</p>

収録刊行物

  • Global Health & Medicine

    Global Health & Medicine 1 (2), 83-87, 2019-12-31

    国立研究開発法人 国立国際医療研究センター

参考文献 (31)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ